Wein Matthew 4

What Happened Matthew Wein — Metagenomi's General Counsel, Compliance Officer and Corporate Secretary — was granted a total of 79,000 award units on April 1, 2026. The filing shows two award lines at $0.00: 11,000 restricted stock units (RSUs) and 68,000 derivative awards (option-like), each reported as acquisitions with no cash paid (total reported value: $0). These are compensation grants, not open-market purchases or sales.

Key Details

• Transaction date(s): April 1, 2026; Form 4 filed April 3, 2026 (two days after the transaction; appears timely under the two-business-day Form 4 rule).
• Award amounts and prices: 11,000 RSUs @ $0.00; 68,000 derivative/option-type awards @ $0.00.
• Shares owned after transaction: Not specified in the filing.
• Vesting/footnotes:
  • F1 (11,000 RSUs): 25% vest on June 5, 2027; remainder vests in 12 equal quarterly installments thereafter, subject to continued service.
  • F2 (68,000 derivative award): 25% vests on April 1, 2027; remainder vests in 36 equal monthly installments thereafter, subject to continued service.
• No indication in the filing that shares were sold, exercised for cash, or withheld for taxes at grant time.

Context These awards are standard equity compensation for an executive and were reported as grants (price $0.00). The RSUs and option-like awards will vest over time subject to continued employment; they do not represent an immediate cash transaction or market sale. For retail investors, grants signal company compensation decisions but do not by themselves indicate a purchase-based bullish signal.